Myriad Genetics Statistics
Total Valuation
Myriad Genetics has a market cap or net worth of $631.77 million. The enterprise value is $711.97 million.
Important Dates
The last earnings date was Tuesday, August 5, 2025, after market close.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Myriad Genetics has 93.04 million shares outstanding. The number of shares has increased by 4.87% in one year.
| Current Share Class | 93.04M |
| Shares Outstanding | 93.04M |
| Shares Change (YoY) | +4.87% |
| Shares Change (QoQ) | +1.20% |
| Owned by Insiders (%) | 2.57% |
| Owned by Institutions (%) | 92.87% |
| Float | 85.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 181.07 |
| PS Ratio | 0.75 |
| Forward PS | 0.73 |
| PB Ratio | 1.63 |
| P/TBV Ratio | 3.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.42, with a Debt / Equity ratio of 0.40.
| Current Ratio | 1.42 |
| Quick Ratio | 1.06 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | 206.13 |
| Debt / FCF | n/a |
| Interest Coverage | -20.18 |
Financial Efficiency
Return on equity (ROE) is -70.03% and return on invested capital (ROIC) is -6.72%.
| Return on Equity (ROE) | -70.03% |
| Return on Assets (ROA) | -5.44% |
| Return on Invested Capital (ROIC) | -6.72% |
| Return on Capital Employed (ROCE) | -16.07% |
| Revenue Per Employee | $308,481 |
| Profits Per Employee | -$146,370 |
| Employee Count | 2,700 |
| Asset Turnover | 0.95 |
| Inventory Turnover | 8.99 |
Taxes
| Income Tax | -25.20M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.27% in the last 52 weeks. The beta is 1.93, so Myriad Genetics's price volatility has been higher than the market average.
| Beta (5Y) | 1.93 |
| 52-Week Price Change | -75.27% |
| 50-Day Moving Average | 5.36 |
| 200-Day Moving Average | 9.05 |
| Relative Strength Index (RSI) | 69.26 |
| Average Volume (20 Days) | 1,620,509 |
Short Selling Information
The latest short interest is 9.37 million, so 10.07% of the outstanding shares have been sold short.
| Short Interest | 9.37M |
| Short Previous Month | 8.50M |
| Short % of Shares Out | 10.07% |
| Short % of Float | 10.94% |
| Short Ratio (days to cover) | 4.06 |
Income Statement
In the last 12 months, Myriad Genetics had revenue of $832.90 million and -$395.20 million in losses. Loss per share was -$4.33.
| Revenue | 832.90M |
| Gross Profit | 586.60M |
| Operating Income | -76.70M |
| Pretax Income | -156.60M |
| Net Income | -395.20M |
| EBITDA | -17.80M |
| EBIT | -76.70M |
| Loss Per Share | -$4.33 |
Full Income StatementBalance Sheet
The company has $74.40 million in cash and $154.60 million in debt, giving a net cash position of -$80.20 million or -$0.86 per share.
| Cash & Cash Equivalents | 74.40M |
| Total Debt | 154.60M |
| Net Cash | -80.20M |
| Net Cash Per Share | -$0.86 |
| Equity (Book Value) | 388.10M |
| Book Value Per Share | 4.17 |
| Working Capital | 84.40M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$22.60 million and capital expenditures -$15.20 million, giving a free cash flow of -$37.80 million.
| Operating Cash Flow | -22.60M |
| Capital Expenditures | -15.20M |
| Free Cash Flow | -37.80M |
| FCF Per Share | -$0.41 |
Full Cash Flow StatementMargins
Gross margin is 70.43%, with operating and profit margins of -9.21% and -47.45%.
| Gross Margin | 70.43% |
| Operating Margin | -9.21% |
| Pretax Margin | -50.47% |
| Profit Margin | -47.45% |
| EBITDA Margin | -2.14% |
| EBIT Margin | -9.21% |
| FCF Margin | n/a |
Dividends & Yields
Myriad Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.87% |
| Shareholder Yield | -4.87% |
| Earnings Yield | -62.55% |
| FCF Yield | -5.98% |
Dividend DetailsAnalyst Forecast
The average price target for Myriad Genetics is $13.50, which is 98.82% higher than the current price. The consensus rating is "Hold".
| Price Target | $13.50 |
| Price Target Difference | 98.82% |
| Analyst Consensus | Hold |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 3.69% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 26, 2009. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 26, 2009 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Myriad Genetics has an Altman Z-Score of 1.78 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.78 |
| Piotroski F-Score | 3 |
